CN116496266A

CN116496266A - Triazine derivatives

Info

Publication number: CN116496266A
Application number: CN202310320094.XA
Authority: CN
Inventors: 吴劲梓
Original assignee: Ascletis Bioscience Co Ltd
Current assignee: Ascletis Bioscience Co Ltd
Priority date: 2022-07-08
Filing date: 2022-11-21
Publication date: 2023-07-28
Also published as: CN115490681A; CN115490681B

Abstract

Triazine derivatives, pharmaceutically acceptable salts, deuterates, prodrugs or metabolites thereof, represented by formula I:wherein R is ₁ 、R ₂ 、R ₃ 、R ₄ 、R _a 、R _b 、R _x X, Y, Z, W, Q, m and hAs defined in the present disclosure.

Description

Triazine derivatives

FIELD

The present disclosure relates generally to the field of pharmaceutical chemistry, and more particularly, to triazine derivatives.

Background

Coronaviruses (CoV) are a family of enveloped positive-strand RNA-pathogenic viruses that can cause acute and chronic diseases including central nervous system diseases, common cold, lower respiratory tract infections, and diarrhea. HcoV-229E and HcoV-OC43 are zoonotic strains first discovered since 1995. In 2003, severe acute respiratory syndrome coronavirus, now designated as SARS-CoV-1, caused the first global human coronavirus pandemic, resulting in 8000 or more progressive respiratory failures and 916 deaths (mortality rates of 10 to 15%). In the next 8 years, human and animal zoonotic coronaviruses HcoV-NL64 and HcoV-HKU1 were found to have significantly reduced mortality. In 2012, the middle east respiratory syndrome coronavirus (MERS-CoV) like SARs was found to have a very high mortality rate, despite a low transmission rate, from 2012 to 2021, 2 months and a total of 2567 patients diagnosed with infection worldwide, with 882 deaths (mortality 34%). In 2020, a new type of coronavirus pneumonia (covd-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently spreading worldwide, has become a world epidemic disease, brings serious challenges to the global public health defense and medical system, and brings uncertainty factors to the world economy. SARS-CoV-2 is a highly pathogenic, pandemic human and animal co-virus belonging to the coronaviridae family with SARS-CoV-1 and MERS-CoV. These three viruses, unlike the other several coronaviruses HcoV-NL63, hcoV-229E, hcoV-OC43 and HCoVHKU1, can cause severe respiratory diseases. Symptoms of SARS-CoV-2 infection range from asymptomatic disease to moderate and severe pneumonia, as well as life threatening complications including hypoxic respiratory failure, acute respiratory distress syndrome, multiple system organ failure, and ultimately death. Even more terrible, the virus is not only highly contagious, but can be transmitted by asymptomatic infected persons and those in both symptomatic and pre-symptomatic stages. Although many different vaccines are currently approved for sale or emergency use worldwide, a significant portion of the population worldwide is not vaccinated due to limitations in its own physical or local medical conditions. In addition, vaccine escape mutations in the S protein of SARS-CoV-2 virus also present potential challenges for vaccine effectiveness, and thus effective anti-new crown drug development remains an urgent task.

Coronaviruses are broken down to release nucleocapsids and viral genomes after entering host cells. The host cell ribosomes translate the Open Reading Frames (ORFs) 1a and 1b of the viral genome into the multimeric proteins pp1a and pp1b, respectively, which encode 16 nonstructural proteins (nsps), while the remaining ORFs encode structural and accessory proteins. The cleavage of PP by 3C-like cysteine protease (3 Clpro) and papain-like cysteine protease (Plpro) results in the formation of nsp2-16, which in turn forms a replication-transcription complex (RTC). These protease activity deletions lead to a viral life cycle arrest. Furthermore, the structure and function of 3Clpro are highly conserved among coronaviruses. Thus, 3Clpro is a potentially effective target for the development of drugs against a broad spectrum of coronaviruses. The 3Clpro inhibitors reported to date include covalent peptidomimetic inhibitors and non-covalent small molecule inhibitors. Although the peptide-like covalent inhibitor has remarkable inhibitory activity on 3Clpro, the covalent inhibitor has poor target selectivity, unpredictable toxic and side effects, poor metabolic stability and the like. The non-covalent small molecule inhibitor is a better choice, however, the currently reported non-covalent small molecule inhibitor is very deficient, and has the problems of single structure, weak enzyme inhibition activity, poor patent medicine property and the like.

SUMMARY

In one aspect, the present disclosure relates to triazine derivatives, pharmaceutically acceptable salts, deuterates, prodrugs, or metabolites thereof, represented by formula I:

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

rx is selected from hydrogen, deuterium, cyano, alkyl, alkenyl, alkynyl; wherein alkyl, alkenyl, alkynyl may be substituted with 1 to 3 deuterium, halogen, hydroxy, cyano or alkoxy groups; the A ring is a five-membered heteroaromatic ring containing N and is surrounded by m optional R _a Substituted;

x, Y, Z are each independently selected from C, N, O or S;

R _a each independently selected from hydrogen, deuterium, halogen, nitro, cyano, oxo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

In another aspect, the present disclosure relates to triazine derivatives, pharmaceutically acceptable salts, deuterates, prodrugs, or metabolites thereof as shown below:

in yet another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a triazine derivative of the present disclosure, a pharmaceutically acceptable salt, deuteride, prodrug, or metabolite thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

In yet another aspect, the present disclosure relates to a method of treating and/or preventing a viral infectious disease comprising administering to a subject in need of such a method a therapeutically effective amount or a prophylactically effective amount of a triazine derivative of the present disclosure, a pharmaceutically acceptable salt, deuteride, prodrug, or metabolite thereof, or a therapeutically effective amount or a prophylactically effective amount of a pharmaceutical composition comprising a triazine derivative of the present disclosure, a pharmaceutically acceptable salt, deuteride, prodrug, or metabolite thereof.

In another aspect, the present disclosure relates to a method of inhibiting a 3C-like cysteine protease (3 Clpro) that would inhibit an effective amount of a triazine derivative of the present disclosure, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, or an effective amount of a pharmaceutical composition comprising a triazine derivative of the present disclosure, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, from contacting with a 3C-like cysteine protease (3 Clpro).

In yet another aspect, the present disclosure relates to the use of a triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof of the present disclosure in the manufacture of a medicament for treating and/or preventing a viral infectious disease in an individual.

In yet another aspect, the present disclosure relates to the use of a triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof of the present disclosure in the preparation of a 3C-like cysteine protease (3 Clpro) inhibitor.

In another aspect, the present disclosure relates to triazine derivatives, pharmaceutically acceptable salts, deuterides, prodrugs, or metabolites thereof of the present disclosure for use in the treatment and/or prevention of viral infectious diseases.

In yet another aspect, the present disclosure relates to triazine derivatives of the present disclosure, pharmaceutically acceptable salts, deuterides, prodrugs, or metabolites thereof for inhibiting 3C-like cysteine protease (3 Clpro).

Detailed description of the preferred embodiments

In the following description, certain specific details are included to provide a thorough understanding of various disclosed embodiments. One skilled in the relevant art will recognize, however, that the embodiments may be practiced without one or more of the specific details, or with other methods, components, materials, etc.

Throughout the specification and claims which follow, unless the context requires otherwise, the words "comprise" and "comprising" are to be construed in an open-ended, inclusive sense, i.e. "including but not limited to.

As used in this disclosure and the appended claims, the singular reference without a quantitative indication includes the plural reference unless the context clearly dictates otherwise.

Reference throughout this specification to "one embodiment" or "an embodiment" or "in another embodiment" or "in certain embodiments" means that a particular reference element, structure, or feature described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrase "in one embodiment" or "in an embodiment" or "in another embodiment" or "in certain embodiments" appearing in various places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, the particular elements, structures, or features may be combined in any suitable manner in one or more embodiments.

It should be understood that, as used in the specification of this disclosure and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a sustained release tablet comprising "pharmaceutically acceptable excipients" includes one pharmaceutically acceptable excipient, or two or more pharmaceutically acceptable excipients.

Definition of the definition

Certain chemical groups named herein are identified previously by simplified symbols indicating the total number of carbon atoms found in the chemical groups shown. For example, C ₇ -C ₁₂ Alkyl describes an alkyl group having a total of 7 to 12 carbon atoms as defined below, and C ₄ -C ₁₂ Cycloalkyl alkyl describes a cycloalkyl alkyl group as defined below having a total of 4 to 12 carbon atoms. The total number of carbon atoms in the reduced symbol does not include carbon that may be present in a substituent of the group.

Accordingly, the following terms, as used in the specification and the appended claims, shall have the following meanings:

the term "oxo" as used in this disclosure refers to an =o group.

The term "cyano" as used in this disclosure refers to a-CN group.

The term "nitro" as used in the present disclosure refers to-NO ₂ A group.

The term "halogen" as used in this disclosure refers to fluorine, chlorine, bromine or iodine.

The term "alkyl" as used in this disclosure refers to a straight or branched hydrocarbon chain group consisting of only carbon and hydrogen atoms, containing no unsaturation, having 1 to 12 carbon atoms, and which is attached to the remainder of the molecule by a single bond. In certain embodiments, the alkyl groups have 1 to 8 carbon atoms. In certain embodiments, the alkyl groups have 1 to 6 carbon atoms. In certain embodiments, the alkyl groups have 1 to 4 carbon atoms. In certain embodiments, illustrative examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. In certain embodiments, the alkyl group may be optionally substituted, i.e., substituted or unsubstituted.

Whenever a radical is described as "optionally substituted," the radical may be unsubstituted or substituted with one or more of the substituents shown. Likewise, when a group is described as "unsubstituted or substituted," the substituents, if substituted, may be selected from one or more of the substituents shown. If no substituents are indicated, it is meant that the indicated "optionally substituted" or "substituted" group may be substituted with one or more groups selected, individually or independently, from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclic, aralkyl, heteroaralkyl, (heteroalicyclic) alkyl, hydroxy, protected hydroxy, alkoxy, aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen, thiocarbonyl, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-amido, N-amido, S-sulfonamide, N-sulfonamide, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanate, isothiocyanate, nitro, silyl, thio, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, amino, monosubstituted amino and disubstituted amino and protected derivatives thereof.

The term "alkoxy" as used in this disclosure refers to the general formula-OR, wherein R is an alkyl group as defined above. In certain embodiments, the alkoxy groups have 1 to 8 carbon atoms. In certain embodiments, the alkoxy groups have 1 to 6 carbon atoms. In certain embodiments, the alkoxy groups have 1 to 4 carbon atoms. In certain embodiments, illustrative examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, tert-pentyloxy, and the like. In certain embodiments, the alkoxy group may be optionally substituted, i.e., substituted or unsubstituted.

The term "cycloalkyl" as used in this disclosure refers to a stable non-aromatic mono-or multicyclic alkyl group consisting of only carbon and hydrogen atoms, which may comprise a fused or bridged ring system having from 3 to 18 carbon atoms, in certain embodiments from 3 to 15 carbon atoms, in certain embodiments from 3 to 10 carbon atoms, and which is saturated and linked to the remainder of the molecule by a single bond. In certain embodiments, illustrative examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Illustrative examples of polycyclic cycloalkyl groups include, but are not limited to, adamantyl, norbornyl, decalinyl, 7-dimethyl-bicyclo [2.2.1] heptyl, and the like. In certain embodiments, cycloalkyl groups may be optionally substituted, i.e., substituted or unsubstituted.

The term "aryl" as used in this disclosure refers to an aromatic mono-or polycyclic hydrocarbon ring system consisting of only hydrogen and carbon and containing from 6 to 18 carbon atoms, wherein the ring system may be partially saturated. In certain embodiments, aryl is C ₆ -C ₁₄ Aryl groups. In certain embodiments, aryl is C ₆ -C ₁₂ Aryl groups. In certain embodiments, aryl is C ₆ -C ₁₀ Aryl groups. In certain embodiments, illustrative examples of aryl groups include, but are not limited to, phenyl, naphthyl, and fluorenyl. In certain embodiments, aryl groups may be optionally substituted, i.e., substituted or unsubstituted.

The term "heteroaryl" as used in this disclosure refers to a 5 to 18 membered aromatic ring group containing 1 to 17 carbon atoms and 1 to 10 heteroatoms selected from nitrogen, oxygen and sulfur. For the purposes of this disclosure, heteroaryl groups may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl group may optionally be oxidized; the nitrogen atom may optionally be quaternized. In certain embodiments, from 4 to 14 atoms may be present on the ring of the heteroaryl group. In certain embodiments, from 5 to 10 atoms may be present on the ring of the heteroaryl group. In certain embodiments, 5 to 6 atoms may be present on the ring of the heteroaryl group. In some embodiments of the present invention, in some embodiments, illustrative examples of heteroaryl groups include, but are not limited to, aza, acridine, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo [ b ] [1,4] dioxaheptyl, 1, 4-benzodioxanyl, benzonaphtofuranyl, benzodioxolyl, benzofuranyl, and benzofuranyl benzodioxanyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl, benzotriazole, benzo [4,6] imidazo [1,2-a ] pyridine, carbazole, cinnolinyl, dibenzofuranyl, dibenzothienyl, imidazopyridinyl, imidazopiperazinyl, imidazopiperidinyl, furyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolinyl, indolizinyl, isoxazolyl, naphthyl, naphthyridinyl, oxadiazolinyl, 2-oxo-azepinyl, oxazolyl, oxiranyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, 2, 3-naphthyridinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, quinidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thienyl. In certain embodiments, heteroaryl groups may be optionally substituted, i.e., substituted or unsubstituted.

The term "physiologically acceptable" as used in this disclosure defines a carrier, diluent or excipient that does not negate the biological activity and properties of the compound.

The term "carrier" as used in this disclosure refers to a substance that effects incorporation of a compound into a cell or tissue.

The term "excipient" as used in this disclosure refers to an inert substance added to a pharmaceutical composition that provides (without limitation) bulk (bulk), consistency, stability, binding ability, lubricity, and disintegration ability, etc. to the composition.

The term "diluent" as used in the present disclosure refers to an ingredient in a pharmaceutical composition that is not pharmaceutically active but may be pharmaceutically necessary or desirable.

The term "mammal" as used in this disclosure is meant to include animals such as dogs, cats, cattle, sheep, horses, and humans. In certain embodiments, the mammal comprises a human.

The term "patient" as used in this disclosure refers to animals (e.g., humans), companion animals (e.g., dogs, cats, or horses), and livestock (e.g., cows, pigs, and sheep). In certain embodiments, the patient is a mammal comprising a male and a female. In certain embodiments, the patient is a human.

The term "pharmaceutically acceptable" or "pharmaceutically acceptable" as used in this disclosure refers to carriers, vehicles, diluents, excipients and/or salts that must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The term "optional" or "optionally" as used in this disclosure means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

As used herein, "pharmaceutically acceptable carrier, diluent or excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent or emulsifier, and the like that have been approved by the U.S. food and drug administration for use in humans or animals.

The term "pharmaceutically acceptable salt" as used in this disclosure includes "acceptable acid addition salts" and "acceptable base addition salts".

"acceptable acid addition salts" refer to those salts that retain the biological effectiveness and properties of the free base, which are biologically or otherwise suitable and are formed using inorganic or organic acids such as, but not limited to, hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, and the like, such as, but not limited to, acetic acid, 2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzene carboxylic acid, 4-acetamidobenzene carboxylic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclohexaneaminosulfonic acid, dodecylsulfuric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, mucic acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1, 5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, glutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, tartaric acid, sulfuric acid, sulfanilic acid, succinic acid, toluenesulfonic acid, tricarboxylic acid, undecylenic acid, and the like.

"acceptable base addition salts" refer to those salts that retain the biological effectiveness and properties of the free acid, which are biologically or otherwise appropriate. These salts are prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. In certain embodiments, the inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and salts of basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benzylamine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. In certain embodiments, the organic base is isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

In general, crystallization will produce solvates of the compounds of the present invention. The term "solvate" as used herein refers to an aggregate comprising one or more of the compound molecules of the present disclosure and one or more solvent molecules. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present disclosure may exist in hydrated forms, including monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate, and the like, as well as in the corresponding solvated forms. The compounds of the present disclosure may be true solvates, while in other cases, the compounds of the present disclosure may retain only sporadic water or be a mixture of water plus a portion of sporadic solvent.

The term "pharmaceutical composition" as used in this disclosure refers to a formulation of a compound described in this disclosure with a medium that delivers a biologically active compound to a mammal, such as a human, as is commonly accepted in the art. Such vehicles include all pharmaceutically acceptable carriers, diluents or excipients.

As used herein, a "therapeutically effective amount" refers to an amount of a compound or combination of compounds that improves, reduces, or eliminates a particular disease or condition and symptoms of a particular disease or condition, or avoids or delays the onset of a particular disease or condition or symptoms of a particular disease or condition. The amount of a compound described in this disclosure that constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age, weight, etc., of the mammal to be treated, but can be routinely determined by one of ordinary skill in the art based on his own knowledge and the present disclosure.

As used herein, "treating" or "treatment" encompasses treatment-related diseases or disease states in a mammal, such as a human, having a related disease or disorder, and includes:

(i) Preventing a disease or a disease state from occurring in a mammal, particularly when the mammal is susceptible to the disease state, but has not been diagnosed with the disease state;

(ii) Inhibiting the disease or disease state, i.e., preventing its occurrence; or alternatively

(iii) The disease or disease state is alleviated even if the disease or disease state regresses or does not progress.

As used in this disclosure, the terms "disease" and "disease state" may be used interchangeably or may be different in that a particular disease or disease state may not have known causative agents (and therefore cannot be interpreted by etiology) and therefore is not recognized as a disease, but rather is considered an undesired disease state or condition in which a clinician has identified more or less of a particular set of symptoms.

The compounds described in this disclosure, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and thus may produce enantiomers, diastereomers, and other stereoisomeric forms, which may be defined as either I-or (S) -, or (D) -or (L) -, of an amino acid, depending on absolute stereochemistry. The present disclosure is intended to include all such possible isomers, as well as racemic and optically pure forms thereof. Chiral synthons or chiral reagents can be used to prepare optically active (+) and (-), I-and (S) -, or (D) -and (L) -isomers, or resolved using conventional techniques, such as HPLC using a chiral column. When a compound described in this disclosure contains an olefinic double bond or other geometric asymmetric center, unless specified otherwise, it is meant that the compound includes both E and Z geometric isomers. Also, all tautomeric forms are meant to be included.

"stereoisomers" refers to compounds that consist of the same atoms bonded by the same bonds, but have different three-dimensional structures that are not interchangeable. The present disclosure encompasses various stereoisomers and mixtures thereof.

"cis-trans isomer" refers to a molecule having the same molecular formula, and because of the presence of a double bond or a ring, free rotation of the bond is hindered, resulting in a spatial arrangement in which the relative distances between adjacent atoms or groups of atoms are different.

"tautomer" refers to the transfer of a proton from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any of the compounds.

The term "prodrug" as used in the present disclosure is intended to mean a compound that can be converted into a biologically active compound of the invention under physiological conditions or by solvolysis. Thus, the term "prodrug" refers to a pharmaceutically acceptable metabolic precursor of a compound of the present disclosure. Prodrugs may be inactive when administered to an individual in need thereof, but are converted in vivo to the active compounds of the present invention. Prodrugs are typically rapidly converted to the disclosed parent compounds in vivo, for example, by hydrolysis in the blood. Prodrug compounds often provide solubility, histocompatibility or delayed release advantages in mammalian organisms (see Bundgard, h., design ofProdrugs (prodrug design) (1985), pp.7-9, 21-24, (Elsevier, amberdam)). Discussion of prodrugs is provided in Higuchi, t., et al, "Pro-drugs as Novel Delivery Systems (prodrug as novel delivery system)", a.c. s.symposium Series, vol.14 and Bioreversible Carriers in Drug Design (bioreversible carrier in drug design), ed.edward b.roche, american Pharmaceutical Association and Pergamon Press,1987, both of which are incorporated herein by reference.

The term "prodrug" as used in the present disclosure is also intended to include any covalently bound carrier that releases the active compounds of the present disclosure in vivo when such prodrugs are administered to a mammalian subject. Prodrugs of the compounds of the present disclosure may be prepared by modifying functional groups present on the compounds of the present disclosure in such a way that these modified materials are cleaved into the parent compounds of the present disclosure in conventional procedures or in vivo. Prodrugs include compounds of the present disclosure wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol functional groups, or amide derivatives of amine functional groups, among others, in the compounds of the present disclosure.

The present disclosure also includes in vivo metabolites of the disclosed compounds. These products are obtained mainly due to enzymatic processes by oxidation, reduction, hydrolysis, amidation, esterification, etc. of the administered compounds. Accordingly, the present disclosure includes a compound produced by a method comprising contacting a compound of the present disclosure with a mammal for a period of time sufficient to produce a metabolite thereof. Identification of metabolites typically occurs by preparing a radiolabeled isotope of a compound of the invention, parenterally administering it to an animal, such as a rat, mouse, guinea pig, monkey, or human, in a detectable dose (e.g., greater than about 0.5 mg/kg), allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from urine, blood, or other biological samples. These products are easy to isolate because they are labeled (others are isolated by using antibodies that are capable of binding to epitopes present in the metabolite). The metabolite structures are determined in a conventional manner, for example by MS, LC/MS or NMR analysis. In general, the analysis of metabolites is performed in the same manner as conventional drug metabolism studies known to those skilled in the art. So long as the metabolite products are not otherwise undetectable in vivo, they are useful in assays for therapeutic dosing of the compounds of the present disclosure.

The term "isotope" as used in this disclosure refers to different nuclides of the same element having the same number of protons and different numbers of neutrons.

The term "abundance" as used in this disclosure refers to the percentage of atoms that an isotope occupies in the natural element to which it belongs.

The term "natural abundance of isotopes" or "natural abundance" as used in this disclosure refers to the percentage of atoms in a natural element that are present in nature that are occupied by various isotopes in that natural element. For example, the natural abundance of isotopes of hydrogen: ¹ H＝99.985％， ² h=0.015%. Isotopic natural abundance of oxygen: ¹⁶ O＝99.76％， ¹⁷ O＝0.04％， ¹⁸ O＝0.20％。

the term "isotopic enrichment index" as used in the present disclosure refers to the ratio of the abundance of an isotope to the natural abundance of the isotope. For example, a deuterium atom with an isotopic enrichment index of 6000 refers to a deuterium atom with an abundance of 90%.

The term "hydrogen" ("H") as used in this disclosure refers to a hydrogen produced by a natural abundance of isotopes ¹ H (99.985%) and ² h (0.015%).

The terms "deuterium" ("D" and "D") as used in this disclosure refer to isotopes of hydrogen (H), one proton and one neutron in the deuterium nucleus, with natural abundance of isotopes of 0.015%. "d _x-y "refers to substitution with x to y deuterium atoms. For example methoxy-d ₃ Refers to CD ₃ O-。

Detailed description of the preferred embodiments

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

In certain embodiments, the a ring is not a heteroaromatic ring containing three N.

In certain embodiments, R _a Each independently selected from hydrogen, deuterium, halogen, cyano, and C ₁ -C ₄ Alkyl, C ₁ -C ₄ Haloalkyl, C ₁ -C ₄ Deuterated alkyl or C ₃ -C ₆ Cycloalkyl groups.

In certain embodiments, R _x Selected from C substituted by one or more deuterium, halogen ₁ -C ₄ An alkyl group.

In certain embodiments, R _a Each independently selected from hydrogen, deuterium, halogen, cyano, methyl, isopropyl, cyclopropyl, -CF ₃ 、-CHF ₂ or-CD ₃ 。

In certain embodiments, R _x For C substituted by one or more deuterium ₁ -C ₄ An alkyl group.

In certain embodiments, Q is Cl or Br; w is deuterium.

In certain embodiments, the five-membered heteroaromatic ring a is selected from:

in certain embodiments, by R _b The substituted benzene ring is selected from the group consisting of:

in certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 200, i.e., the abundance of deuterium atoms as substituents is 3%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 400, i.e., the abundance of deuterium atoms as substituents is 6%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 666.67, i.e., the abundance of deuterium atoms as substituents is 10%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 1000, i.e., the abundance of deuterium atoms as substituents is 15%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 2000, i.e., the abundance of deuterium atoms as substituents is 30%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 3333.33, i.e., the abundance of deuterium atoms as substituents is 50%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 4000, i.e., the abundance of deuterium atoms as substituents is 60%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 5000, i.e., the abundance of deuterium atoms as substituents is 75%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6000, i.e., the abundance of the deuterium atom as a substituent is 90%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6333.33, i.e., the abundance of the deuterium atom as a substituent is 95%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6466.67, i.e., the abundance of deuterium atoms as substituents is 97%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6533.33, i.e., the abundance of deuterium atoms as substituents is 98%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6566.67, i.e., the abundance of deuterium atoms as substituents is 98.5%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6600, i.e., the abundance of deuterium atoms as substituents is 99%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6633.33, i.e., the abundance of deuterium atoms as substituents is 99.5%.

In certain embodiments, the deuterium atom as a substituent has an isotopic enrichment index of 6660, i.e., the abundance of deuterium atoms as substituents is 99.9%.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 60%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 75%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 90%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 95%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 97%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 98%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 98.5%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 99%, while other isotopes have their natural abundance.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, isomers, prodrugs, or metabolites thereof of the present disclosure have an abundance of deuterium atoms as substituents of at least 99.5%, while other isotopes have their natural abundance.

in certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, deuterated, prodrugs, or metabolites thereof of the present disclosure have excellent therapeutic effects on viral infectious diseases.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, deuterated, prodrugs, or metabolites thereof of the present disclosure have excellent therapeutic effects on coronavirus infectious diseases.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, deuterates, prodrugs, or metabolites thereof of the present disclosure are 3Clpro non-covalent small molecule inhibitors having significant activity.

In certain embodiments, the triazine derivatives, pharmaceutically acceptable salts, deuterated, prodrugs, or metabolites thereof of the present disclosure are effective to increase blood concentration, extend half-life, and significantly reduce single dose.

Pharmaceutical composition

In yet another aspect, the present disclosure is directed to a pharmaceutical composition comprising a therapeutically effective amount of a triazine derivative represented by formula I, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof,

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl,

and a pharmaceutically acceptable carrier, excipient or diluent.

In certain embodiments, the pharmaceutical compositions of the present disclosure include a physiologically acceptable surfactant, carrier, diluent, excipient, lubricant, suspension, film forming material, coating aid, or combination thereof, and a compound of the present disclosure, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical arts and are described, for example, in Remington's Pharmaceutical Sciences (ramington pharmaceutics), 18 ^th Ed., mack Publishing Co., easton, pa., 1990), the entire contents of which are incorporated herein by referenceReference is made to the following.

Preservatives, stabilizers, dyes, sweeteners, fragrances, perfumes and the like may be provided in the pharmaceutical compositions. For example, sodium benzoate, ascorbic acid, and esters of parahydroxybenzoic acid may be added as preservatives. In addition, antioxidants and suspensions may be used.

In various embodiments, alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surfactants; sucrose, glucose, lactose, starch, crystalline cellulose, mannitol, light anhydrous silicate, magnesium aluminate, methyl magnesium aluminate silicate, synthetic aluminum silicate, calcium carbonate, calcium bicarbonate, calcium hydrogen phosphate, calcium hydroxymethyl cellulose and the like can be used as excipients; magnesium stearate, talc, hardened oil, etc. can be used as a smoothing agent; coconut oil, olive oil, sesame oil, peanut oil, soybean may be used as a suspension or lubricant; cellulose acetate which is a derivative of a saccharide such as cellulose or sugar, or methyl acetate-methacrylate copolymer which is a derivative of polyethylene can be used as a suspension; and plasticizers such as phthalate esters and the like may be used as the suspension.

Suitable routes of administration may include, for example, oral, rectal, transdermal, topical or enteral; parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary, intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injection. The compounds can also be administered at a predetermined rate and/or in prolonged and/or timed, pulsed, in sustained or controlled release dosage forms including depot injections (depots), osmotic pumps, pills, transdermal (including electrotransport) patches, and the like.

The pharmaceutical compositions of the present disclosure may be produced in known manner, for example, by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting procedures.

Thus, in accordance with the present disclosure, the pharmaceutical compositions employed may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Suitable formulations depend on the route of administration selected. Any known techniques, carriers and excipients may be used as appropriate and understood in the art.

The injection can be prepared in the following conventional forms: as a solution or suspension, suitable for preparation of a solid dosage form of the solution or suspension prior to injection, or as an emulsion. Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride and the like. In addition, if desired, the injectable pharmaceutical composition may contain minor amounts of non-toxic auxiliary substances such as wetting agents, pH buffers and the like. Physiologically suitable buffers include, but are not limited to, hank's solution, ringer's solution, or physiological saline buffer. If desired, absorption enhancing agents (e.g., liposomes) may be used.

For transmucosal administration, penetrants appropriate to the barrier to be permeated may be used in the formulation.

Pharmaceutical formulations for parenteral administration, for example, by bolus injection or continuous infusion, comprise aqueous solutions of the active compound in water-soluble form. In addition, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or other organic oils such as soybean oil, grapefruit oil, or almond oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, for example sodium hydroxymethylcellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that enhance the solubility of the compounds to produce high concentration formulations. The injectable preparation and the additional preservative may be present in unit dosage form, for example, in ampoules or in multi-dose containers. The composition may take such dosage forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and the composition may contain agents such as suspensions, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable carrier, such as sterile pyrogen-free water, prior to use.

For oral administration, the compounds can be readily formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art. For oral ingestion by a patient to be treated, such carriers enable the compounds of the invention to be formulated as tablets, pills, troches, capsules, liquids, gels, syrups, slurries, suspensions and the like. A pharmaceutical formulation for oral administration can be obtained by: the active compound is admixed with solid excipients, the resulting mixture is optionally ground and the mixture of granules is processed, if desired after adding suitable auxiliaries, to obtain tablets or dragee cores. Suitable excipients include, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations, for example corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents can be added, for example crosslinked polyvinylpyrrolidone, agar or alginic acid or an alginate such as sodium alginate. The lozenge cores are suitably coated. For this purpose, concentrated sugar solutions may be used, which may optionally comprise gum arabic, talc, polyvinylpyrrolidone, carbopol gel (carbopol gel), polyethylene glycol and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. To identify or characterize different combinations of active compound doses, dyes or pigments may be added to the tablet or lozenge coating. For this purpose, concentrated sugar solutions may be used, which may optionally comprise gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. To identify or characterize different combinations of active compound doses, dyes or pigments may be added to the tablet or lozenge coating.

Pharmaceutical formulations that can be used for oral administration include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin, such as glycerol or sorbitol, and a plasticizer. The push-fit capsules can contain the active ingredient in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredient may be dissolved or suspended in a suitable liquid, for example a fatty oil, liquid paraffin or liquid polyethylene glycol. In addition, stabilizers may be added. All formulations for oral administration should be in a dosage suitable for such administration.

For buccal administration, the compositions may be formulated in the form of tablets or lozenges in accordance with conventional methods.

For administration by inhalation, the compounds used in the present disclosure are conveniently delivered in the form of a spray from a pressurized pack or nebulizer using a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve that delivers a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The present disclosure also discloses various pharmaceutical compositions for use in delivery, including intraocular, intranasal, and otic delivery, as are well known in the pharmaceutical arts. Penetrants appropriate to such applications are generally known in the art. Pharmaceutical compositions for intraocular delivery include aqueous ophthalmic solutions of the active compound in water-soluble form, such as eye drops, or in gellan gum form or hydrogel form; an ophthalmic ointment; ophthalmic suspensions, such as microparticles, small polymer particles contained in a liquid carrier medium, liposoluble formulations, and microspheres; an ophthalmic intercalator. For stability and comfort, these suitable pharmaceutical formulations are most often and preferably formulated as sterile, isotonic and buffered pharmaceutical formulations. Pharmaceutical compositions for intranasal delivery may also include drops and sprays, which are typically prepared to mimic nasal secretions in many respects to ensure that normal ciliated function is maintained. As is well known to those skilled in the art, suitable formulations are most often and preferably isotonic, lightly buffered to maintain pH between 5.5 and 6.5, and most often and preferably include an antimicrobial preservative and a suitable pharmaceutical stabilizer. Pharmaceutical formulations for in-the-ear delivery include suspensions and ointments for topical application in the ear. Common solvents for such otic formulations include glycerin and water.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the aforementioned formulations, the compounds may also be formulated as depot formulations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, suitable polymers or hydrophobic materials (e.g., emulsions in acceptable oils) or ion exchange resins may be used to formulate the compounds, or as sparingly soluble derivatives, such as, for example, a sparingly soluble salt.

For hydrophobic compounds, a suitable pharmaceutical carrier may be a co-solvent system comprising benzyl alcohol, a non-polar surfactant, a water miscible organic polymer, and an aqueous phase. The common co-solvent system used was a VPD co-solvent system of 3% w/v benzyl alcohol, 8% w/v non-polar surfactant POLYSORBATE (PolySORBATE) 80. TM. And 65% w/v polyethylene glycol 300, with the volume of solution being made up by absolute ethanol. Of course, the proportion of the co-solvent system can be varied considerably without compromising its solubility and toxicity characteristics. In addition, the co-solvent composition may be varied: for example, other low toxicity non-polar surfactants may be used in place of polysorbate 80TM; the fragment size of polyethylene glycol can be changed; other biocompatible polymers such as polyvinylpyrrolidone and the like may be substituted for polyethylene glycol; and other sugars or polysaccharides may be substituted for glucose.

Alternatively, other delivery systems for hydrophobic drug compounds may be employed. Well-known examples of delivery media or carriers for hydrophobic drugs are liposomes and emulsions. Although generally at the expense of higher toxicity, certain organic solvents, such as dimethyl sulfoxide, may also be employed. In addition, the compounds may be delivered using a slow release system, such as a semipermeable matrix of solid hydrophobic polymer containing the therapeutic agent. Many slow release materials are known and established by those skilled in the art. Depending on its chemical nature, a slow release capsule may release the compound over several weeks to 100 days.

Agents for intracellular administration are administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes. Upon formation of liposomes, all molecules present in the aqueous solution are incorporated into the aqueous interior. The contents of the liposome are not only not affected by the external microenvironment, but are efficiently delivered to the cytoplasm due to the fusion of the liposome with the cell membrane. Liposomes can be coated with tissue specific antibodies. Liposomes will be targeted to and selectively taken up by the desired organ. Alternatively, small hydrophobic organic molecules may be administered directly intracellularly.

Therapeutic methods and uses

In yet another aspect, the present disclosure relates to a method of treating and/or preventing a viral infectious disease comprising administering to a subject in need thereof a therapeutically effective amount or a prophylactically effective amount of a triazine derivative represented by formula I, a pharmaceutically acceptable salt, deuterated, prodrug, or metabolite thereof, or a therapeutically effective amount or a prophylactically effective amount of a pharmaceutical composition comprising a triazine derivative represented by formula I, a pharmaceutically acceptable salt, deuterated, prodrug, or metabolite thereof:

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

R _a each independently selected from hydrogen, deuterium, halogen, nitro, cyano, oxo, optionally substituted alkyl, optionally takenSubstituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

In certain embodiments, illustrative examples of viruses that can be used in the present disclosure include, but are not limited to, middle east syndrome associated coronavirus (MERS-CoV), severe acute respiratory syndrome associated coronavirus (SARS-CoV), influenza a virus, influenza b virus, novel coronavirus pneumonia (covd-19), spanish influenza virus, arenavirus, bunyavirus, rabies virus, avian influenza virus, polio virus, rhinovirus, adenovirus, ebola virus, enterovirus, hepatitis a virus, hepatitis c virus, hepatitis e virus, enterovirus, HIV virus, echovirus, filovirus, measles virus, yellow fever virus, japanese encephalitis virus, west nile virus, newcastle disease virus, RS virus, vesicular stomatitis virus, mumps virus, dengue virus, coxsackie virus, rotavirus, or tobacco mosaic virus.

In certain embodiments, illustrative examples of individuals that can be used in the present disclosure include, but are not limited to, mammals.

In certain embodiments, the individual capable of being used in the present disclosure is a human.

In another aspect, the present disclosure relates to a method of inhibiting a 3C-like cysteine protease (3 Clpro) comprising contacting an effective amount of a triazine derivative represented by formula I, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, or an effective amount of a pharmaceutical composition comprising a triazine derivative represented by formula I, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, with a 3C-like cysteine protease (3 Clpro):

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

In yet another aspect, the present disclosure relates to the use of a triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to formula I in the manufacture of a medicament for treating and/or preventing a viral infectious disease in a subject:

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

In yet another aspect, the present disclosure relates to the use of a triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, according to formula I:

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

R _a each independently selected from hydrogen, deuterium, halogen, nitro, cyano, oxo, optionally substituted alkyl, optionally substituted alkoxyOptionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

In another aspect, the present disclosure relates to triazine derivatives, pharmaceutically acceptable salts, deuterates, prodrugs or metabolites thereof, of formula I for use in the treatment and/or prevention of viral infectious diseases:

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

m＝1、2、3、4；

R _b Selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

In yet another aspect, the present disclosure relates to a triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, of formula I for inhibiting a 3C-like cysteine protease (3 Clpro):

wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

x, Y, Z are each independently selected from C, N, O or S;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, substituted alkyl.

Administration method

The compound or pharmaceutical composition may be administered to the patient by any suitable method. Non-limiting examples of methods of administration include (a) administration by the oral route, including administration in capsules, tablets, granules, sprays, syrups, or other such forms; (b) Administration by non-oral route, such as rectal, vaginal, intraurethral, intraocular, intranasal or intraaural, including administration as an aqueous suspension, oily formulation, etc., or as drops, sprays, suppositories, ointments, salves, etc.; (c) Administration by subcutaneous injection, intraperitoneal injection, intravenous injection, intramuscular injection, intradermal injection, intraorbital injection, intracapsular injection, intraspinal injection, intrasternal injection, etc., including infusion pump delivery; (d) Local (local) administration, such as injection directly in the kidney or heart area, for example by reservoir implantation; and I topical (topicaly) administration; a suitable mode of administration, as will be appreciated by those skilled in the art, is for the compounds of the invention to be in contact with living tissue.

The most suitable route depends on the nature and severity of the disease state being treated. Those skilled in the art are also familiar with determining methods of administration (oral, intravenous, inhalation, subcutaneous, rectal, etc.), dosage forms, appropriate pharmaceutical excipients, and other considerations related to the delivery of the compounds to a subject in need thereof.

Pharmaceutical compositions suitable for administration include those which contain an effective amount of the active ingredient to achieve its intended effect. The dosage required for a therapeutically effective amount of the disclosed pharmaceutical compositions depends on the route of administration, the type of animal being treated, including humans, and the physical characteristics of the particular animal under consideration. The dosage may be adjusted to achieve the desired effect, but will depend on the following factors: weight, diet, concurrent medication, and other factors recognized by those skilled in the art of medicine. More specifically, a therapeutically effective amount refers to an amount of a compound effective to prevent, reduce or ameliorate symptoms of a disease, or to extend the life of an individual receiving treatment. The actual ability of those skilled in the art to determine a therapeutically effective amount is well within the scope of the detailed disclosure provided herein.

As will be apparent to those skilled in the art, the dosage and particular mode of administration used for in vivo administration will vary depending upon the age, weight and type of mammal being treated, the particular compound being used, and the particular use for which such compound is being used. The aim of determining an effective dosage level, i.e. the dosage level necessary to determine the desired effect, can be achieved by the person skilled in the art using conventional pharmacological methods. Generally, the human clinical application of the compound is started at lower dosage levels, with the dosage level increasing until the desired effect is achieved. Alternatively, using established pharmacological methods, acceptable in vitro studies can be used to establish effective dosages and routes of administration for the compositions identified by the present methods.

In non-human animal studies, the use of potential compounds begins at higher dosage levels, with the dosage decreasing until the desired effect is no longer achieved or the adverse side effects disappear. The dosage range may be wide depending on the intended effect and the therapeutic indication. Generally, the dosage may be from about 10 μg/kg body weight to 500mg/kg body weight, preferably from about 100 μg/kg body weight to 200mg/kg body weight. Alternatively, as will be appreciated by those skilled in the art, the dose may be based on and calculated from the surface area of the patient.

Each physician is able to select the exact formulation, route of administration and dosage of the pharmaceutical composition of the invention, depending on the condition of the patient. Generally, the dosage of the composition administered to the patient may range from about 0.5mg/kg to 1000mg/kg of patient body weight. The dose may be administered alone or in two or more doses over a single day or days, depending on the patient's needs. Where the human dosage of the compound is established for at least some conditions, the present invention will use those same dosages, or dosages ranging from about 0.1% to 500% of the established human dosage, more preferably dosages ranging from 25% to 250% of the established human dosage. In the absence of a defined human dose, as in the case of the newly discovered pharmaceutical compounds, a suitable human dose can be obtained from ED ₅₀ Or ID ₅₀ Values, or other suitable values from in vitro or in vivo studies, were extrapolated as quantified by toxicity studies and efficacy studies in animals.

It should be noted that due to toxicity and organ dysfunction, the attending physician will know how and when to terminate, interrupt or adjust administration. Conversely, if the clinical response is inadequate (toxicity is excluded), the attending physician will also know to adjust the treatment to a higher level. The size of the dose administered in the treatment of the condition of interest will vary with the severity of the disease state being treated and the route of administration. The severity of the disease state may be assessed, for example, in part by standard prognostic assessment methods. Furthermore, the dose and possibly the frequency of doses will also vary according to the age, weight, and response of the individual patient. Protocols comparable to those discussed above may be used in veterinary medicine.

While the exact dosage may be determined on a drug-by-drug basis, in most cases some generalization can be made with respect to the agent. The daily dosage regimen for adult patients is, for example, an oral dose of 0.1mg to 2000mg of each active ingredient, preferably 1mg to 1000mg of each active ingredient, for example 5 to 500mg of each active ingredient. In other embodiments, the intravenous, subcutaneous or intramuscular dose of each active ingredient used is from 0.01mg to 1000mg, preferably from 0.1mg to 800mg, for example from 1 to 200mg. In the case of administration of pharmaceutically acceptable salts, the dosage may be calculated as the free base. In certain embodiments, the composition is administered 1 to 4 times daily. Alternatively, the compositions of the invention may be administered by continuous intravenous infusion, preferably at doses of up to 1000mg of each active ingredient per day. As will be appreciated by those skilled in the art, in certain instances, it is necessary to administer the disclosed compounds in amounts exceeding or far exceeding the preferred dosage ranges described above in order to effectively and rapidly treat a rapidly developing disease or infection. In certain embodiments, the compound is administered during a continuous treatment period, e.g., one or more weeks, or months or years.

The dosage and dosage interval may be individually adjusted to provide a plasma level of the active moiety sufficient to maintain a modulating effect or Minimum Effective Concentration (MEC). The MEC for each compound was different, but the MEC could be assessed from in vitro data. The required dose to achieve MEC depends on the individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

The use of MEC values also enables the dosing interval to be determined. The composition should be administered using a treatment regimen that maintains plasma levels above MEC for 10-90% of the time, preferably 30-90% of the time, and more preferably 50-90% of the time.

In the case of local administration or selective absorption, the effective local concentration of the drug is independent of plasma concentration.

The amount of composition administered will, of course, depend on the individual to be treated, on the weight of the individual, the severity of the affliction, the mode of administration and the discretion of the prescribing physician.

The potency and toxicity of the compounds disclosed herein can be assessed using known methods. For example, the toxicology of a particular compound or subset of compounds sharing certain chemical moieties can be established by assaying the toxicity of a cell line, such as a mammalian cell line and preferably a human cell line, in vitro. The results of such studies are generally predictive of toxicity in animals such as mammals, or more specifically, in humans. Alternatively, toxicity of a particular compound in an animal model such as mouse, rat, rabbit or monkey can be determined using known methods. The potency of a particular compound can be determined using several well-known methods, such as in vitro methods, animal models, or human clinical trials. There are well-known in vitro models for almost every type of disease state, including but not limited to cancer, cardiovascular disease and various immune dysfunctions. Similarly, acceptable animal models can be used to determine the efficacy of chemicals to treat these disease states. When selecting a model to determine efficacy, the skilled artisan is able to select the appropriate model, dosage and route of administration, as well as treatment regimen, under the direction of the art. Of course, human clinical trials can also be used to determine the efficacy of a compound in humans.

If desired, the composition may be placed in a packaging or dispensing device which may contain one or more unit dosage forms containing the active ingredient. The package may for example comprise a metal or plastic foil, such as a blister pack. The packaging or dispensing device may carry instructions for administration. The packaging or dispensing device may also carry precautions associated with the container, the precautions being prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which precautions reflect approval of the pharmaceutical form by the agency for human or veterinary administration. Such precautions may be, for example, labels approved by the U.S. food and drug administration for prescription drugs, or approved product specifications. Compositions comprising the compounds of the invention formulated in compatible pharmaceutical carriers may also be prepared in suitable containers and labeled for use in the treatment of the indicated disease state.

Preparation of the Compounds

The following reaction scheme illustrates a method for preparing a compound of the present disclosure, i.e., a compound of formula I or a pharmaceutically acceptable salt, deuterate, prodrug or metabolite thereof in the form of a stereoisomer, cis-trans isomer, tautomer or mixture thereof,

Wherein R is ₁ 、R ₂ 、R ₃ 、R ₄ 、R _a 、R _b 、R _x X, Y, Z, W, Q, m and h are as defined in the disclosure.

It is to be understood that combinations of substituents and/or variables of the formulae depicted in the following description are permissible only if such combinations result in stable compounds.

It will also be appreciated by those skilled in the art that in the methods described below, the functional groups of the intermediate compounds may need to be protected by appropriate protecting groups. These functional groups include hydroxyl, amino, mercapto and carboxylic acid. Suitable protecting groups for the hydroxyl group include trialkylsilyl or diarylsilyl groups (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino groups include t-butoxycarbonyl, benzyloxycarbonyl, fluorenylmethoxycarbonyl and the like. Suitable protecting groups for sulfhydryl groups include-C (O) -R "(wherein R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl, and the like. Suitable protecting groups for carboxylic acids include alkyl, aryl or aralkyl esters.

Protecting groups may be added or removed according to standard techniques known to those skilled in the art and as described herein.

The use of protecting groups is described in detail in Green, t.w. and p.g. m. wuts, protective Groups in Organic Synthesis (organically synthesized protecting groups) (1999), 3rd Ed. The protecting group may also be a polymeric resin such as Wang resin or chlorinated 2-chlorotrityl resin.

Those skilled in the art will also appreciate that while these protective derivatives of the compounds of the present disclosure may not themselves be pharmacologically active, they may be administered to a mammal and then metabolized in the body to form the pharmacologically active compounds of the present disclosure. These derivatives may thus be described as "prodrugs". All prodrugs of the compounds of the present disclosure are included within the scope of the present disclosure.

The following schemes illustrate methods for preparing compounds of the present disclosure. It will be appreciated that those skilled in the art can prepare these compounds by analogous methods or by methods known to those skilled in the art. It will also be appreciated that one skilled in the art can make other compounds of formula I not explicitly illustrated below, using the appropriate starting ingredients and modifying the synthesis parameters as desired, in a manner similar to that described below. Typically, the starting ingredients are obtained from conventional commercial sources, or synthesized from sources known to those skilled in the art or prepared as described herein.

In the following schemes, the structures of the groups are as defined in the disclosure.

In general, compounds of formula I of the present disclosure can be synthesized following the general procedure described in reaction scheme 1 below.

In equation 1, the structures of the groups are as defined in the disclosure. The compounds may each exist in the form of stereoisomers, cis-trans isomers, tautomers or mixtures thereof.

Hereinafter, the present disclosure will be explained in detail by the following examples in order to better understand the aspects of the present disclosure and advantages thereof. However, it should be understood that the following examples are non-limiting and are merely illustrative of certain embodiments of the present disclosure.

Examples

Although any person skilled in the art is able to prepare the compounds of the present application in accordance with the general techniques disclosed above, for convenience, more detailed techniques for synthesizing the compounds of the present application are provided elsewhere in this specification. In addition, all reagents and reaction conditions used in the synthesis are known to those skilled in the art and are available from common commercial sources. For example, various reagents used in the examples, including deuterated reagents, are available from Sigma-Aldrich Company Ltd. The various cell lines and enzymes used in the examples are commercially available, for example, from the China academy of sciences typical culture Collection Commission cell Bank.

Unless otherwise indicated herein, ¹ HNMR is measured using deuterated dimethyl sulfoxide at a frequency of 500MHz at about 20-30 ℃. Standard NMR abbreviations are used: s = single peak; d = bimodal; dd = bimodal; t = triplet; q = quartet; p = quintuplet peak; m = multiple peaks; br=broadband.

Preparation example 1

Synthesis of Compound 1

(1) Synthesis of Compound 1-C

Compound 1-A (1 g,4.36 mmol) was dissolved in acetonitrile (25 mL), and to the above solution were added potassium carbonate (0.72 g,5.23 mmol) and compound 1-B (1.09 g,4.80 mmol), and the mixture was heated under reflux for 2h. Cooling to room temperature, diluting the reaction solution with ethyl acetate, suction-filtering, concentrating the filtrate, and separating and purifying by column chromatography to obtain the compound 1-C (1.55 g, 95%).

(2) Synthesis of Compound 1-D

To compound 1-C (1.50 g,4.02 mmol) was added TFA (10 mL), and the reaction was stirred at room temperature overnight, concentrated, slurried with isopropyl ether, suction filtered, and the filter cake collected and dried to give compound 1-D (1.15 g, 90%).

(3) Synthesis of Compound 1-F

Compound 1-D (1 g,3.15 mmol) was dissolved in DMF (25 mL), and potassium carbonate (0.52 g,3.78 mmol) and compound 1-E (0.46 g,3.47 mmol) were added to the above solution and reacted under reflux with heating for 2h. Cooling to room temperature, diluting the reaction solution with ethyl acetate, suction filtering, concentrating the filtrate, and separating and purifying by column chromatography to obtain the compound 1-F (1.13 g, 87%).

(4) Synthesis of Compound 1

To a solution of compounds 1-F (700 mg,1.70 mmol) and 1-G (345 mg,1.87 mmol) in tetrahydrofuran was added dropwise a solution of LiHMDS in tetrahydrofuran (1M, 1.87mL,1.87 mmol) at 0℃and stirred for 3h at 0℃and then transferred to room temperature and stirred for 40min. After completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution (10 mL), extracted with ethyl acetate (10 mL. Times.3), the organic phases were combined, washed with saturated brine, and dried over Na ₂ SO ₄ Drying, filtration, concentration, and column chromatography purification gave compound 1 (663 mg, 73%).

Preparation example 2

Synthesis of Compound 16

(1) Synthesis of Compound 16-C

Compound 1-A (1 g,4.36 mmol) was dissolved in acetonitrile (25 mL), and to the above solution were added potassium carbonate (0.8 g,5.79 mmol) and compound 16-B (1.10 g,4.82 mmol), and the mixture was heated under reflux for 3h. Cooling to room temperature, diluting the reaction solution with ethyl acetate, suction filtering, concentrating the filtrate, and separating and purifying by column chromatography to obtain the compound 1-C (1.6 g, 98%).

(2) Synthesis of Compound 16-D

To compound 16-C (1.6 g,4.29 mmol) was added TFA (15 mL), and the reaction was stirred at room temperature overnight, concentrated, slurried with isopropyl ether, suction filtered, and the cake was collected and dried to give compound 16-D (1.16 g, 85%).

(3) Synthesis of Compound 16-F

Compound 16-D (1.1 g,3.47 mmol) was dissolved in DMF (30 mL), and potassium carbonate (0.6 g,4.34 mmol) and compound 16-E (0.5 g,3.74 mmol) were added to the solution and heated under reflux for 1h. Cooling to room temperature, diluting the reaction solution with ethyl acetate, suction filtering, concentrating the filtrate, and separating and purifying by column chromatography to obtain the compound 16-F (1.2 g, 83%).

(4) Synthesis of Compound 16

To a tetrahydrofuran solution of compound 16-F (800 mg,1.93 mmol) and 1-G (370 mg,2.0 mmol) at 0℃was added dropwise a tetrahydrofuran solution of LiHMDS (1M, 2.1mL,2.1 mmol), and stirring was continued at 0℃for 3 hours, and then transferred to room temperature and stirred for 1 hour. After completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution (20 mL), extracted with ethyl acetate (20 mL. Times.3), the organic phases were combined, washed with saturated brine, and dried over Na ₂ SO ₄ Drying, filtration, concentration, and column chromatography purification gave compound 16 (703 mg, 68%).

Preparation example 3

Synthesis of Compound 24

(1) Synthesis of Compound 24

To a tetrahydrofuran solution of compound 16-F (750 mg,1.81 mmol) and 24-G (360 mg,1.98 mmol) at 0℃was added dropwise a tetrahydrofuran solution of LiHMDS (1M, 2.0mL,2.0 mmol), and stirring was continued at 0℃for 2 hours, followed by transfer to room temperature and stirring for 1 hour. After completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution (20 mL), extracted with ethyl acetate (20 mL. Times.3), the organic phases were combined, washed with saturated brine, and dried over Na ₂ SO ₄ Drying, filtration, concentration, and column chromatography purification produced compound 24 (652 mg, 67%).

Other methods of synthesis of the compounds were as in example 1, with only the replacement of the corresponding starting materials.

Preparation example 4

Synthesis of Compound 25

(1) Synthesis of Compound 25-C

Compound 1-A (1 g,4.36 mmol) was dissolved in acetonitrile (25 mL), and to the above solution were added potassium carbonate (0.72 g,5.23 mmol) and compound 25-B (1.09 g,4.80 mmol), and the mixture was heated under reflux for 2h. Cooling to room temperature, diluting the reaction solution with ethyl acetate, suction filtering, concentrating the filtrate, and separating and purifying by column chromatography to obtain the compound 25-C (1.40 g, 85%).

(2) Synthesis of Compound 25-D

To compound 25-C (1.40 g,3.75 mmol) was added TFA (10 mL), and the reaction was stirred at room temperature overnight, concentrated, slurried with isopropyl ether, suction filtered, and the cake was collected and dried to give compound 25-D (1.1 g, 91%).

(3) Synthesis of Compound 25-F

Compound 25-D (1 g,3.15 mmol) was dissolved in DMF (25 mL), and potassium carbonate (0.52 g,3.78 mmol) and compound 25-E (0.37 g,3.15 mmol) were added to the solution and reacted by heating 75 for 2h. Cooling to room temperature, diluting the reaction solution with ethyl acetate, suction filtering, concentrating the filtrate, and separating and purifying by column chromatography to obtain the compound 25-F (1.10 g, 88%).

(4) Synthesis of Compound 25

To a tetrahydrofuran solution of compounds 25-F (700 mg,1.75 mmol) and 24-G (350 mg,1.93 mmol) at 0deg.C was added dropwise a tetrahydrofuran solution of LiHMDS (1M, 2.1mL,2.1 mmol), and stirring was continued for 3 hours at 0deg.C, and then transferred to room temperature and stirred for 40 minutes. After completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution (10 mL), extracted with ethyl acetate (10 mL. Times.3), the organic phases were combined, washed with saturated brine, and dried over Na ₂ SO ₄ Drying, filtration, concentration, and column chromatography purification gave compound 25 (350 mg, 38%).

Preparation example 5

Synthesis of Compound 70

(1) Synthesis of Compound 70

To a tetrahydrofuran solution of compound 25-F (700 mg,1.75 mmol) and 70-G (408 mg,1.93 mmol) at 0℃was added dropwise a tetrahydrofuran solution of LiHMDS (1M, 2.1mL,2.1 mmol), and stirring was continued for 3 hours at 0℃and then transferred to room temperature and stirred for 40 minutes. After completion of the reaction, a saturated ammonium chloride solution (10 mL) quenched, extracted with ethyl acetate (10 mL. Times.3), the combined organic phases washed with saturated brine, dried over anhydrous Na ₂ SO ₄ Drying, filtration, concentration, and column chromatography purification gave compound 70 (300 mg, 31%).

Preparation example 6

Synthesis of Compound 110

(1) Synthesis of Compound 110

To a tetrahydrofuran solution of compound 25-F (700 mg,1.75 mmol) and 110-G (354 mg,1.93 mmol) at 0deg.C was added dropwise a tetrahydrofuran solution of LiHMDS (1M, 2.1mL,2.1 mmol), and stirring was continued at 0deg.C for 3 hours, and then transferred to room temperature and stirred for 40 minutes. After completion of the reaction, the reaction mixture was quenched with saturated ammonium chloride solution (10 mL), extracted with ethyl acetate (10 mL. Times.3), the organic phases were combined, washed with saturated brine, and dried over Na ₂ SO ₄ Drying, filtration, concentration, and column chromatography purification gave compound 110 (260 mg, 28%).

The other compound synthesis method is as in example 4, and the corresponding raw materials are only needed to be replaced.

Biological example 1

In vitro potency test of potential antiviral Compounds for antiviral efficacy against SARS-CoV-2

1. Purpose(s)

The in vitro antiviral activity of potential antiviral compounds against the SARS-CoV-2 amikates hCoV-19/USA/MD HP20874/2021 (B.1.1.529) strain and hCoV-19/USA/Chicago IL/2022 (BA.5.2) was evaluated in an in vitro cell infection system.

2. Material

2.1 reference Compounds

The reference compound adefovir is provided by IITRI. 8 concentration points and 3 compound wells were set for assay analysis.

2.2 cell lines

Human lung cancer cell line Calu-3 cells were cultured in minimal essential medium (EMEM) containing 10% heat-inactivated fetal bovine serum (Gibco, cat. No. A3840001), 100U/ml penicillin and streptomycin.

2.3 reagents and instruments

The primary reagents used in this assay were anti-coronavirus Nucleoprotein (NP) monoclonal antibodies, peroxidase-conjugated goat anti-mouse IgG, ABTS peroxidase.

The main instruments used in this test were an enzyme-labeled instrument and an ELISA plate reader.

3. Method of

Calu-3 cells were seeded in 96-well plates containing different multiple dilutions of the compound, with the addition of the Omikou variant strain with MOI=0.01. Washing after incubation for 1 hourThe virus-containing supernatant was replaced with medium containing the compound in a double dilution and containing 5.+ -. 2% CO ₂ Is cultured in a humidifying chamber at 37.+ -. 2 ℃ for 48 hours. Absorbance at 402nm was measured using a microplate reader.

Absorbance readings for each well were collected by SoftMaxPro software and imported into a Microsoft Excel spreadsheet for further calculations. Outliers were detected by Grubbs test built in Graphpad Prism 9. For each well, percent Viral Reduction (PVR) calculation was calculated using the formula, and the half inhibition concentration (EC) was calculated by calculating the concentration-response curve for each test sample by 4-parameter nonlinear regression curve fitting ₅₀ )。

Biological example 2

Pharmacokinetic property testing of rat model

Oral administration: the compounds were dosed at 10mg/kg with Solutol: PEG400: tween80: saline=10:40:2:48. After 0.25h,0.5h,1h,2h,4h,8h,10h,12h,24h, continuously taking blood from the fundus venous plexus, placing into an EP tube containing EDTA, centrifuging at 8000rpm/min for 5min, taking upper plasma, freezing at-80deg.C, and analyzing by LC-MS/MS

Intravenous administration: the compound was dosed with 1mg/kg with 10% dmso/30% peg400/60% water). After administration, 0.0833h,0.25h,0.5h,1h,2h,4h,8h,12h,24h, continuously taking blood from the ocular fundus venous plexus, placing into an EP tube containing EDTA, centrifuging at 8000rpm/min for 5min, collecting upper plasma, freezing at-80deg.C, and analyzing by LC-MS/MS

And according to the blood concentration-time data obtained by the test, adopting WinNonlin software to calculate the pharmacokinetic parameters.

Biological example 3

Macaca fascicularis pharmacokinetic property test

Oral administration: the compound was dosed at 2mg/kg with Solutol: PEG400:tween 80:saline=10:40:2:48. Continuously taking blood at 0.25h,0.5h,1h,2h,4h,8h,10h,12h,24h, placing into an EP tube containing EDTA, centrifuging at 8000rpm/min for 5min, collecting upper plasma, freezing at-80deg.C, and analyzing by LC-MS/MS

Intravenous administration: the compound was dosed with 1mg/kg with 10% dmso/30% peg400/60% water). After 0.0833h,0.25h,0.5h,1h,2h,4h,8h,12h,24h, continuously taking blood, placing into an EP tube containing EDTA, centrifuging at 8000rpm/min for 5min, taking upper plasma, freezing at-80deg.C, and analyzing by LC-MS/MS

In this disclosure, relational terms such as first and second, and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions.

All patents, patent application publications, patent applications, and non-patent publications cited in this specification are herein incorporated by reference in their entirety.

From the foregoing it will be appreciated that, although specific embodiments of the disclosure have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the disclosure. Accordingly, the scope of the present disclosure should be limited only by the attached claims.

Claims

1. Triazine derivatives, pharmaceutically acceptable salts, deuterates, prodrugs or metabolites thereof, represented by formula I:

Wherein the method comprises the steps of

R ₁ 、R ₂ 、R ₃ 、R ₄ Selected from H or D;

rx is selected from hydrogen, deuterium, cyano, C ₁ -C ₄ Alkyl, C ₂ -C ₄ Alkenyl, C ₂ -C ₄ Alkynyl; wherein alkyl, alkenyl, alkynyl may be substituted with 1 to 3 deuterium, halogen, hydroxy, cyano or alkoxy groups; the A ring is a five-membered heteroaromatic ring containing N and is surrounded by m optional R _a Substituted;

x, Y, Z are each independently selected from C, N, O or S;

R _a each independently selected from hydrogen, deuterium, halogen, nitro, cyano or C substituted with 1 to 3 deuterium, halogen, hydroxy, cyano groups ₁ -C ₄ Alkyl, C ₃ -C ₆ Cycloalkyl;

m＝1、2、3、4；

R _b selected from hydrogen, deuterium, halogen, cyano, substituted alkoxy;

h＝2、3、4；

w or Q is selected from hydrogen, deuterium, halogen, C ₁ -C ₄ Substituted alkyl.

2. The triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof of claim 1 wherein the a ring is not a heteroaromatic ring containing three N.

3. The triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to claim 1 wherein

R _a Each independently selected from hydrogen, deuterium, halogen, cyano, and C ₁ -C ₄ Alkyl, C ₁ -C ₄ Haloalkyl, C ₁ -C ₄ Deuterated alkyl or C ₃ -C ₆ Cycloalkyl;

R _x selected from C substituted by one or more deuterium, halogen ₁ -C ₄ An alkyl group.

4. The triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to claim 1 wherein

R _a Each independently selected from hydrogen, deuterium, halogen, cyano, methyl, isopropyl, cyclopropyl, -CF ₃ 、-CHF ₂ or-CD ₃ ；

R _x For C substituted by one or more deuterium ₁ -C ₄ An alkyl group.

5. The triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to claim 1 wherein

Q is Cl or Br;

w is deuterium.

6. The triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof of claim 1 wherein five membered heteroaryl ring a is selected from:

7. the triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to claim 6 wherein five membered heteroaromatic ring a is selected from:

8. the triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to claim 1 wherein R _b The substituted benzene ring is selected from the group consisting of:

9. the triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to claim 8 wherein R _b The substituted benzene ring is selected from the group consisting of:

10. the triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof of claim 9 wherein is represented by R _b The substituted benzene ring is selected from the group consisting of:

11. Triazine derivatives, pharmaceutically acceptable salts, deuterates, prodrugs or metabolites thereof, as shown below:

12. a pharmaceutical composition comprising a therapeutically effective amount of the triazine derivative of any one of claims 1-11, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

13. Use of a triazine derivative, pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof according to any one of claims 1 to 11, or a pharmaceutical composition according to claim 12 in the manufacture of a medicament for the treatment and/or prevention of a viral infectious disease in a subject.

14. The use of claim 13, wherein the virus is selected from the group consisting of middle east syndrome associated coronavirus (MERS-CoV), severe acute respiratory syndrome associated coronavirus (SARS-CoV), influenza a virus, influenza b virus, novel coronavirus (SARS-CoV-2), spanish influenza virus, arenavirus, bunyavirus, rabies virus, avian influenza virus, bone marrow poliovirus, rhinovirus, adenovirus, ebola virus, enterovirus, hepatitis a virus, hepatitis c virus, hepatitis e virus, enterovirus, HIV virus, ico virus, filovirus, measles virus, yellow fever virus, japanese encephalitis virus, west nile virus, newcastle disease virus, RS virus, vesicular stomatitis virus, mumps virus, dengue virus, coxsackie virus, rotavirus, or tobacco mosaic virus.

15. The use of claim 13 or 14, wherein the individual is selected from a mammal.

16. The use of claim 15, wherein the mammal is a human.

17. Use of the triazine derivative of any one of claims 1 to 11, a pharmaceutically acceptable salt, deuterate, prodrug, or metabolite thereof, or the pharmaceutical composition of claim 12, for the preparation of a 3C-like cysteine protease (3 CLpro) inhibitor.